Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025
Rhea-AI Summary
Immunocore (Nasdaq: IMCR) will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026. The company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) to discuss results and provide a business and portfolio update.
Investors can access the live audio webcast via the 'Events' page in the Investors section at www.immunocore.com; a replay will be available for a limited time.
Positive
- None.
Negative
- None.
News Market Reaction – IMCR
In the Feb 18 session, IMCR gained 0.40%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 30 | R&D leadership change | Neutral | -1.4% | Head of R&D departure with internal promotions and streamlined R&D structure. |
| Jan 09 | Strategic priorities update | Positive | -0.1% | Outlined 2026 strategic priorities and cash of about $864M with slight price dip. |
| Nov 10 | Investor conferences | Neutral | +4.5% | Announced presentations at two November 2025 investor conferences with webcasts. |
| Nov 07 | Clinical data update | Positive | +6.0% | Phase 1 hepatitis B data showing manageable safety and pharmacodynamic activity. |
| Nov 06 | Earnings and update | Positive | +2.6% | Q3 2025 results with higher KIMMTRAK sales and near breakeven net income. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has mostly seen price moves that align with the underlying tone, with only one notable divergence on a strategic update.
Over the past several months, Immunocore has reported growing KIMMTRAK revenue, essentially breakeven earnings, and advanced multiple Phase 3 programs, as highlighted in the Nov 6, 2025 earnings. Clinical progress included positive Phase 1 hepatitis B data on Nov 7, 2025, which coincided with a stronger positive move. Corporate visibility has been supported by investor conferences and a recent R&D leadership transition announced on Jan 30, 2026. Today’s scheduling of the Q4 and full-year 2025 results fits into this cadence of operational and financial updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025
(OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 18 February 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the fourth quarter and year ended December 31, 2025 on Wednesday, February 25, 2026.
Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) to discuss its financial results and provide a business and portfolio update.
Audio Webcast
The call will be webcast live and can be accessed by visiting ‘Events’, under ‘Events and Presentations’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay will also be made available for a limited time.
Conference Call Details:
Domestic (toll-free): 877-405-1239
International (toll): +1 201-389-0851
About Immunocore
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.
Contact Information
Immunocore
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on LinkedIn: @Immunocore
Investor Relations
Clayton Robertson / Morgan Morse
T: +1 (215) 384-4781
E: ir@immunocore.com
